Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers

[1]  Yih-Ru Wu,et al.  Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model , 2015, Brain, Behavior, and Immunity.

[2]  F. Gage,et al.  Mutant Huntingtin Promotes Autonomous Microglia Activation via Myeloid Lineage-determining Factors Fold Difference from the Mean , 2022 .

[3]  S. Tabrizi,et al.  HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. , 2014, Brain : a journal of neurology.

[4]  Chris Frost,et al.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.

[5]  S. Tabrizi,et al.  Mutant huntingtin impairs immune cell migration in Huntington disease. , 2012, The Journal of clinical investigation.

[6]  Ronald Boellaard,et al.  Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[11C]PK11195 brain PET studies , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  R. Reilmann,et al.  Assessment of involuntary choreatic movements in Huntington's disease—Toward objective and quantitative measures , 2011, Movement disorders : official journal of the Movement Disorder Society.

[8]  Yen F. Tai,et al.  Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study , 2011, Human brain mapping.

[9]  R. Reilmann,et al.  Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[10]  Daniel Rueckert,et al.  Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation , 2010, NeuroImage.

[11]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[12]  T. Möller,et al.  Distinct neuroinflammatory profile in post-mortem human Huntington's disease , 2009, Neuroreport.

[13]  Federico E. Turkheimer,et al.  Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[11C]PK11195 brain PET studies , 2008, 2008 IEEE Nuclear Science Symposium Conference Record.

[14]  Marios Politis,et al.  Hypothalamic involvement in Huntington's disease: an in vivo PET study. , 2008, Brain : a journal of neurology.

[15]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[16]  Alessandra Bertoldo,et al.  Novel Reference Region Model Reveals Increased Microglial and Reduced Vascular Binding of 11C-(R)-PK11195 in Patients with Alzheimer's Disease , 2008, Journal of Nuclear Medicine.

[17]  Daniel Rueckert,et al.  Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest , 2008, NeuroImage.

[18]  H. Nielsen,et al.  Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[19]  Alexander Hammers,et al.  A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195 , 2007, NeuroImage.

[20]  Daniel Rueckert,et al.  Automatic detection and quantification of hippocampal atrophy on MRI in temporal lobe epilepsy: A proof-of-principle study , 2007, NeuroImage.

[21]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  Alexander Gerhard,et al.  Microglial activation in presymptomatic Huntington's disease gene carriers. , 2005, Brain : a journal of neurology.

[23]  H. Nakanishi.  Microglial functions and proteases , 2003, Molecular Neurobiology.

[24]  F. Turkheimer,et al.  Reference and target region modeling of [11C]-(R)-PK11195 brain studies. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  Val J Lowe,et al.  NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Kris Thielemans,et al.  Correction of head movement on PET studies: comparison of methods. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Daniel Rueckert,et al.  Automatic anatomical brain MRI segmentation combining label propagation and decision fusion , 2006, NeuroImage.

[28]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[29]  H. Robertson,et al.  DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations , 2006, Brain Research.

[30]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[31]  E. Bixler,et al.  IL-6 and Its Circadian Secretion in Humans , 2005, Neuroimmunomodulation.

[32]  P. Patterson,et al.  Activation of the IκB Kinase Complex and Nuclear Factor-κB Contributes to Mutant Huntingtin Neurotoxicity , 2004, The Journal of Neuroscience.

[33]  E. Bixler,et al.  Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. , 2004, The Journal of clinical endocrinology and metabolism.

[34]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[35]  C. Svarer,et al.  Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  J. Edwardson,et al.  Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double‐stranded RNA , 2003, Glia.

[37]  C L Galli,et al.  Interleukin-1β Enhances NMDA Receptor-Mediated Intracellular Calcium Increase through Activation of the Src Family of Kinases , 2003, The Journal of Neuroscience.

[38]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[39]  D. Craufurd,et al.  Behavioral changes in Huntington Disease. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

[40]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[41]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[42]  F E Turkheimer,et al.  Multiresolution Analysis of Emission Tomography Images in the Wavelet Domain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  J. Penney,et al.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.

[44]  David J. Brooks,et al.  Measuring Neurotransmitter Release with PET: Methodological Issues , 1998 .

[45]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[46]  M. MacDonald,et al.  CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.

[47]  M. MacDonald,et al.  Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum , 1997, The Journal of Neuroscience.

[48]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[49]  G. Kreutzberg.  Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[50]  Junying Yuan,et al.  Functional role of interleukin 1 beta (IL-1 beta) in IL-1 beta- converting enzyme-mediated apoptosis , 1996, The Journal of experimental medicine.

[51]  A. Prochiantz,et al.  The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[53]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[54]  E. Hirsch,et al.  Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form , 1995, Nature Genetics.

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[56]  J H McColl,et al.  Statistical methods in neuroimaging with particular application to emission tomography , 1994, Statistical methods in medical research.

[57]  D. Brock,et al.  A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. , 1993, Molecular and cellular probes.

[58]  O. Riess,et al.  Improved PCR conditions for the stretch of (CAG)n repeats causing Huntington's disease. , 1993, Human molecular genetics.

[59]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[60]  J. Stroop.  Studies of interference in serial verbal reactions. , 1992 .